Lipo-ImmunoTech was founded on the goal of advancing anti-cancer strategies and/or neurodegenerative diseases that have strong mechanistic data and can dramatically benefit patient health.

Contact
Mount Pleasant, SC ogretmen@musc.edu and mehrotr@musc.edu

Innovative solutions for highly complex health conditions.

Lipo-ImmunoTech advances innovative anti-cancer and neurodegenerative treatments with strong data to improve health. We focus on lipid metabolism/signaling and immunotherapy, offering a dual approach to target cancer and enhance immune system activity.

Know More

Lipo ImmunoTech

15+

Research papers have been published
Know More

We are in Clinic: NCT0570285


WE HAVE AN STTR Phase II GRANT R42CA239952

Current Therapies in Development

Lipo-ImmunoTech is at the forefront of developing innovative therapies targeting cancer and neurodegenerative diseases.

Cancer-specific Ceramide analog DRUGS

  • Novel chemotherapeutics not traditionally targeted for therapy
  • Attacks cancer cells through mitochondria
  • Re-sensitization of cancer cells towards normal progression of cellular death
  • Sphingolipid biology is a rising target for cancer treatment
  • Multiple publications and early pre-clinical work already performed
  • These compounds have indications to improve neurodegenerative disorders, such as Alzheimer’s Disease and ALS by improving mitochondrial quality control in neurons

Expansion of T cells for personalized tumor treatment

  • Novel activation technology for T cell development from patient’s cells for superior anti-cancer functions
  • Complementary system for CAR-T cell therapy
  • T-cell therapy that does not need active genetic manipulation
  • Ready for clinical trials because of the patient’s cells involved in therapy using TILs or CAR-T cells that we generate using a GMP-certified clean cell facility
ABOUT US

Lipo-ImmunoTech was founded on the goal of advancing anti-cancer strategies and/or neurodegenerative diseases that have strong mechanistic data and can dramatically benefit patient health. Our company offers innovation in anti-cancer strategies utilizing lipid metabolism/signaling and immuno-therapy. Both pathways for treatment provides a two-prong approach for attacking cancer through novel chemotherapeutics by targeting lipid metabolism/signaling and by strengthening the natural anti-cancer activity of the immune system, which provide unique set of expertise and leadership.

Know More

Research Infrastructure

Lipo-ImmunoTech is a spin-off company from the Medical University of South Carolina. Founders Drs. Ogretmen and Mehrotra are field-leading scientists, who maintain NIH-funded laboratories and active publications in top journals. Our research space is located at the Hollings Cancer Center and directly overseen by Drs. Ogretmen and Mehrotra. Our medical director, Dr. Lilly, is a physician scientist, who is one of the leading oncologists at the Hollings Cancer Center with national and international reputation. 

Know More